메뉴 건너뛰기




Volumn 78, Issue 6, 2014, Pages 1315-1333

Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases

(22)  Pan, Wei Jian a   Köck, Kathleen a   Rees, William A a   Sullivan, Barbara A b   Evangelista, Christine M b   Yen, Mark c,h   Andrews, Jane M d   Radford Smith, Graham L e,f   Prince, Peter J a   Reynhardt, Kaz O a   Doherty, David R a   Patel, Sonal K a   Krill, Christine D a   Zhou, Kefei b   Shen, Jing b   Smith, Lynn E b   Gow, Jason M a   Lee, Jonathan b   Treacy, Anthony M g   Yu, Zhigang b   more..


Author keywords

AMG 181; PK PD; T cell trafficking; Ulcerative colitis; 4 7 integrin

Indexed keywords

ABRILUMAB; C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN; PLACEBO; MONOCLONAL ANTIBODY;

EID: 84919340208     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12418     Document Type: Article
Times cited : (29)

References (56)
  • 1
    • 2442563304 scopus 로고    scopus 로고
    • Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
    • Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
    • (2004) Gastroenterology , vol.126 , pp. 1504-1517
    • Loftus, E.V.1
  • 2
    • 58149390157 scopus 로고    scopus 로고
    • An update on the epidemiology of inflammatory bowel disease in Asia
    • Thia KT, Loftus EV, Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-82.
    • (2008) Am J Gastroenterol , vol.103 , pp. 3167-3182
    • Thia, K.T.1    Loftus, E.V.2    Sandborn, W.J.3    Yang, S.K.4
  • 5
    • 70949107842 scopus 로고    scopus 로고
    • Inflammatory bowel disease
    • Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
    • (2009) N Engl J Med , vol.361 , pp. 2066-2078
    • Abraham, C.1    Cho, J.H.2
  • 6
    • 77952692062 scopus 로고    scopus 로고
    • Association between Helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature
    • Luther J, Dave M, Higgins PD, Kao JY. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 2010; 16: 1077-84.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 1077-1084
    • Luther, J.1    Dave, M.2    Higgins, P.D.3    Kao, J.Y.4
  • 11
    • 0032849823 scopus 로고    scopus 로고
    • Review article: Efficacy of infliximab in Crohn's disease-induction and maintenance of remission
    • discussion 38
    • Rutgeerts PJ. Review article: efficacy of infliximab in Crohn's disease-induction and maintenance of remission. Aliment Pharmacol Ther 1999; 13 (Suppl. 4): 9-15; discussion 38.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 9-15
    • Rutgeerts, P.J.1
  • 18
    • 79952788410 scopus 로고    scopus 로고
    • Review article: Remission rates achievable by current therapies for inflammatory bowel disease
    • Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870-9.
    • (2011) Aliment Pharmacol Ther , vol.33 , pp. 870-879
    • Peyrin-Biroulet, L.1    Lemann, M.2
  • 20
    • 79957927386 scopus 로고    scopus 로고
    • Anti-TNF therapy: Safety aspects of taking the risk
    • Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011; 10: 563-8.
    • (2011) Autoimmun Rev , vol.10 , pp. 563-568
    • Rosenblum, H.1    Amital, H.2
  • 21
    • 0037145037 scopus 로고    scopus 로고
    • Integrins: Bidirectional, allosteric signaling machines
    • Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
    • (2002) Cell , vol.110 , pp. 673-687
    • Hynes, R.O.1
  • 22
    • 84867576762 scopus 로고    scopus 로고
    • Exclusive antagonism of the alpha (4) beta(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
    • Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ. Exclusive antagonism of the alpha(4) beta(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012; 18: 2107-19.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 2107-2119
    • Fedyk, E.R.1    Wyant, T.2    Yang, L.L.3    Csizmadia, V.4    Burke, K.5    Yang, H.6    Kadambi, V.J.7
  • 28
    • 0031092633 scopus 로고    scopus 로고
    • Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells
    • Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997; 158: 2099-106.
    • (1997) J Immunol , vol.158 , pp. 2099-2106
    • Picarella, D.1    Hurlbut, P.2    Rottman, J.3    Shi, X.4    Butcher, E.5    Ringler, D.J.6
  • 30
    • 84861318436 scopus 로고    scopus 로고
    • Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis
    • Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012; 20: 1-18.
    • (2012) Inflammopharmacology , vol.20 , pp. 1-18
    • Thomas, S.1    Baumgart, D.C.2
  • 34
    • 22844438117 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences
    • Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005; 353: 414-6.
    • (2005) N Engl J Med , vol.353 , pp. 414-416
    • Berger, J.R.1    Koralnik, I.J.2
  • 35
    • 26844538111 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis
    • author reply 44-6
    • Berger T, Deisenhammer F. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N Engl J Med 2005; 353: 1744-6; author reply 44-6.
    • (2005) N Engl J Med , vol.353 , pp. 1744-1746
    • Berger, T.1    Deisenhammer, F.2
  • 36
    • 37548998990 scopus 로고    scopus 로고
    • Treating multiple sclerosis in the natalizumab era: Risks benefits clinical decision making and a comparison between North American and European Union practices
    • Giovannoni G, Kinkel P, Vartanian T. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Rev Neurol Dis 2007; 4: 184-93.
    • (2007) Rev Neurol Dis , vol.4 , pp. 184-193
    • Giovannoni, G.1    Kinkel, P.2    Vartanian, T.3
  • 42
    • 84919401099 scopus 로고    scopus 로고
    • NIH. Safety tolerability, pharmacokinetics and pharmacodynamics of AMG 181 in healthy subjects and subjects with mild to moderate ulcerative colitis (NCT01164904) In, 7/1/2010 Edition, US National Institute of Health Available at last accessed 04 January 2014
    • NIH. Safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 181 in healthy subjects and subjects with mild to moderate ulcerative colitis (NCT01164904). In, 7/1/2010 Edition, US National Institute of Health, 2010. Available at http://clinicaltrials.gov/ct2/results? term=01164904&Search=Search (last accessed 04 January 2014).
    • (2010)
  • 43
    • 84919401098 scopus 로고    scopus 로고
    • NIH, AMG 181 phase 2 study in subjects with moderate to severe ulcerative colitis (NCT01694485). In, 9/24/2012 Edition, US National Institute of Health last accessed 04 January 2014
    • NIH. AMG 181 phase 2 study in subjects with moderate to severe ulcerative colitis (NCT01694485). In, 9/24/2012 Edition, US National Institute of Health, 2012. http://clinicaltrials.gov/ct2/results?term=01694485&Search =Search (last accessed 04 January 2014).
    • (2012)
  • 44
    • 84919401097 scopus 로고    scopus 로고
    • NIH, AMG 181 in subjects with moderate to severe Crohn's disease (NCT01696396). In, 9/27/2012 Edition, US National Institute of Health last accessed 04 January 2014
    • NIH. AMG 181 in subjects with moderate to severe Crohn's disease (NCT01696396). In, 9/27/2012 Edition, US National Institute of Health, 2012. http://clinicaltrials.gov/ct2/results? term=01696396&Search=Search (last accessed 04 January 2014).
    • (2012)
  • 45
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 46
    • 84919401096 scopus 로고    scopus 로고
    • National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0, Bethesda, MD: NCI, NIH, DHHS
    • National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. Bethesda, MD: NCI, NIH, DHHS, 2009.
    • (2009)
  • 47
    • 84872832486 scopus 로고    scopus 로고
    • One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2
    • Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
    • (2013) Aliment Pharmacol Ther , vol.37 , pp. 204-213
    • Sandborn, W.J.1    Colombel, J.F.2    D'Haens, G.3    Van Assche, G.4    Wolf, D.5    Kron, M.6    Lazar, A.7    Robinson, A.M.8    Yang, M.9    Chao, J.D.10    Thakkar, R.11
  • 48
    • 84919342463 scopus 로고    scopus 로고
    • Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial
    • Sandborn W, Sands B, Rutgeerts P, Sankoh S, Rosario M, Milch C, Fox I. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial. Inflamm Bowel Dis 2012; 18: S1.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. S1
    • Sandborn, W.1    Sands, B.2    Rutgeerts, P.3    Sankoh, S.4    Rosario, M.5    Milch, C.6    Fox, I.7
  • 50
    • 77952778634 scopus 로고    scopus 로고
    • Serum albumin concentration: A predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
    • Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
    • (2010) Int J Clin Pharmacol Ther , vol.48 , pp. 297-308
    • Fasanmade, A.A.1    Adedokun, O.J.2    Olson, A.3    Strauss, R.4    Davis, H.M.5
  • 51
    • 84858793037 scopus 로고    scopus 로고
    • Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms
    • Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
    • (2012) Clin Pharmacol Ther , vol.91 , pp. 635-646
    • Ordas, I.1    Mould, D.R.2    Feagan, B.G.3    Sandborn, W.J.4
  • 54
    • 33745262396 scopus 로고    scopus 로고
    • Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
    • Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-34.
    • (2006) Inflamm Bowel Dis , vol.12 , pp. 524-534
    • Konikoff, M.R.1    Denson, L.A.2
  • 56
    • 33144460914 scopus 로고    scopus 로고
    • Laboratory markers in IBD: Useful magic or unnecessary toys
    • Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
    • (2006) Gut , vol.55 , pp. 426-431
    • Vermeire, S.1    Van Assche, G.2    Rutgeerts, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.